T7-Exo/siGalectin-9 effectively delivers siGalectin-9 to GBM cells, activates TLR 7-IRF 5 pathway, polarize macrophages to M1 phenotype, enhances the phagocytosis of macrophages on GBM cells, thereby suppressing the antitumor effect of CD8 + T cells and inflammatory response [87]. The gene discussed is CD8A; the disease is glioblastoma.